Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)

详细信息    查看全文

• 作者：Gregory S. Basarab ; Pamela J. Hill ; C. Edwin Garner ; Ken Hull ; Oluyinka Green ; Brian A. Sherer ; P. Brian Dangel ; John I. Manchester ; Shanta Bist ; Sheila Hauck ; Fei Zhou ; Maria Uria-Nickelsen ; Ruth Illingworth ; Richard Alm ; Mike Rooney ; Ann E. Eakin
• 刊名：Journal of Medicinal Chemistry
• 出版年：2014
• 出版时间：July 24, 2014
• 年：2014
• 卷：57
• 期：14
• 页码：6060-6082
• 全文大小：1008K
• ISSN：1520-4804

文摘

AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.